Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy.

ABSTRACT:

Objectives

To describe the seasonal respiratory syncytial virus (RSV) burden in Italy considering the current prophylaxis strategy with palivizumab recommended only for high-risk infants (representing only 4.4% of an estimated birth cohort) and to evaluate the potential benefits of a new prophylaxis strategy targeting all infants with nirsevimab.

Methods

A static decision analytic model previously used in the US was adapted to evaluate the RSV-related health and cost outcomes associated with nirsevimab versus standard of care (SoC) for the prevention of RSV medically attended lower respiratory tract infections (RSV-MA-LRTIs). Monthly probabilities of RSV infections, health events, mortality, and complications associated with RSV infections were obtained from the literature.

SUBMITTER: Marcellusi A 

PROVIDER: S-EPMC11783691 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature